Heart failure drug vericiguat put to the test in everyday care
NCT ID NCT06486844
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study looked at data from 500 people in Germany who started taking vericiguat for chronic heart failure with reduced ejection fraction. Researchers wanted to see how well the drug works outside of clinical trials, in routine medical care. They tracked deaths and hospitalizations to measure real-world effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- vericiguat (Verquvo)
- What this could lead to
- If successful, this study could confirm that vericiguat works as well in everyday practice as it did in clinical trials, helping doctors better manage heart failure.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. It also only looks at existing data, so it cannot prove cause and effect.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEART FAILURE WITH REDUCED EJECTION FRACTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bayer
Wuppertal, 42096, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart failure drug puzzle: study aims to untangle polypharmacy risks
- Salt pills for heart failure? new study investigates
- Smartphone app may help heart failure patients get the right meds faster
- Which workout is best for heart failure? new study aims to find out
- Could a common steroid speed heart shock recovery?
- Smart alerts aim to cut heart failure hospital stays